H. Lundbeck A/S (Lundbeck) today announced that new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity, ...

Precision brain imaging of individuals with Parkinson’s disease reveals that the affected circuit is best characterized as a previously described network of brain regions called the somato-cognitive ...

Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri ...

Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people worldwide. Published in the Journal of Neuroscience, new research from the ...

Researchers have uncovered a shared brain cell breakdown mechanism behind Alzheimer’s and Parkinson’s diseases, revealing how two different proteins can disrupt neurons in the same devastating way.

BETHESDA, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

A mutant DJ-1 gene causes recessive Parkinson's disease, but the molecular mechanism of this process has not been well studied. To understand how DJ-1 hydrolyzes cyclic 3-phosphoglyceric anhydride—a ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced that the U.S. Food and Drug Administration (FDA) ...

Significant side effects of this medication include extrapyramidal symptoms, or involuntary movements and muscle stiffness, which can lead to motor deficits like those seen in patients with ...

Lundbeck Advances Parkinson's Research With New Phase 1B Data At AD/PDTM 2026. Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented ...